3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
3
Unknown
2
Terminated
1
Sponsor Class
OTHER
4
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Pain
1
Neoplasms
1
Interventions
Injections
54
Cisplatin
49
Paclitaxel
48
Carboplatin
43
Gemcitabine
38
pembrolizumab
36
Docetaxel
36
Capecitabine
36
Drug Therapy
34
anlotinib
25
Bevacizumab
25
Fluorouracil
24
Cyclophosphamide
24
icotinib
23
Oxaliplatin
20
fludarabine
19
Pemetrexed
17
Leucovorin
16
Irinotecan
16
Temozolomide
14
Nivolumab
14
Doxorubicin
14
Cetuximab
14
camrelizumab
13
apatinib
13
Trastuzumab
12
Rituximab
11
Fulvestrant
11
Etoposide
11
tesetaxel
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Unknown
×
INDUSTRY
×
Hydromorphone
×
Clear all
NCT03564548
2021-07-28
REBORN
Tetra Bio-Pharma
Phase 2
Unknown
20 enrolled
NCT00822614
2009-01-14
FINDS
Akela Pharma, Inc.
Phase 3
Unknown
500 enrolled